Table 3.
The most important characteristics of different CS-NGs (selection).
| CS-NGs | DC/DLE (%) | DR (%) | Mw/DD of CS | Ref. |
|---|---|---|---|---|
| Myricetin CS-NGs | 1.33 mg/mL of polymeric mass | 83% (after 4 h, pH 1.2) reached the equilibrium state after 12 h |
CS LMw 20 kDa DD 90% |
[63] |
| Triclosan/ Flurbiprofen CS-NGs |
DLE: Triclosan (93.67 ± 3.51%), Flurbiprofen (96.33 ± 2.08%) | 80% (burst release in first 2 h) |
CS MMw 190–310 kDa DD 84% |
[60] |
| Doxorubicin CS/CMCS-NGs |
0.5 mg/mL with DLE of 71.84 ± 3.1 % | 200 ng/mL in vivo release in plasma (after 7 h) |
CS LMw, 10 kDa DD 89%; CMCS MMw, 12 kDa, DD 81%, DS 92% |
[64] |
| Doxorubicin GlyCS-NGs |
2 mg/mL with DLE of 78 ± 3.1 | 23% (pH 6.8) and 8% (pH 7.4) after 4 h; 20% (pH 7.4) and 59% (pH 6.8) after 24 h |
Gly CS Mw 250 kDa, DD 82.7% |
[65] |
| 5-Fluororuacil CS/PLGA-NGs | DLE of 39 ± 0.2% in CS-NGs | 25–30% (pH 7.0), after 24 h 70–85% (pH 6.0), after 24 h |
CS MMw Mw * DD 75% |
[66] |
| Bleomycin CS-NGs | DLE of 54.0 ± 0.95% in CS-NGs | 35% (pH 7.0), 55% (pH 4.0), 85% (pH 6.0), after 24 h |
CS MMw Mw * DD 75% |
[67] |
* unspecified.